Florence Séjourné
Chief Executive Officer
PRECISION MEDICINES TO TACKLE THE IMPACT OF SEVERE BACTERIAL INFECTIONS
AUROBAC THERAPEUTICS is a biopharmaceutical company dedicated to the fight against severe bacterial infections and their consequences in acute hospital settings
Medical Needs
Antimicrobial Resistance (AMR) has become one of the world’s greatest threats to public health, with over 1,27 million deaths worldwide today, and an estimated 10 million deaths a year by 2050. Because of AMR, infections are increasingly difficult to treat, and the resulting medical needs are high.
It is estimated that 63.5% of cases of antibiotic-resistant bacterial infections are healthcare-associated. Acute respiratory infections associated with healthcare (HAP/VAP) continue to be a frequent complication of hospital care, accounting for 22% of all nosocomial infections. These respiratory infections are the most common source of infections leading to sepsis, accounting for 47% of cases.
Research & Development
AUROBAC THERAPEUTICS’ R&D strategy encompasses patient- and pathogen-targeted programs designed to tackle both the causes and consequences of serious bacterial infections and AMR. Central to this approach is the adoption of innovative diagnostic strategies aimed at facilitating patient stratification and optimizing treatment outcomes.
Our Team
Driven by a shared vision, our team is at the forefront of developing a new generation of precision drugs and improving outcomes for patients in urgent need.
Latest News
AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance
AUROBAC ©2024 – Legal Notice – Privacy Statement – Photo Credits